<DOC>
	<DOCNO>NCT00125372</DOCNO>
	<brief_summary>The purpose study learn effect lung cancer 2 new drug , Tarceva Targretin , give combination surgical removal tumor . Tarceva approve Food Drug Administration ( FDA ) lung cancer . Targretin approve treatment cutaneous T-cell lymphoma . This combination drug experimental .</brief_summary>
	<brief_title>Study Tarceva Targretin Stage I-II Lung Cancer</brief_title>
	<detailed_description>Erlotinib 150mg bexarotene 400mg/m2 administer orally 7-9 day prior thoracotomy . Plasma sample collect day surgery along tissue sample day thoracotomy . Analyses do resected specimen compare pre-study diagnostic specimen .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Resectable stage I II nonsmallcell lung cancer Prior tissue biopsy ( cytology ) available research analysis Adequate hepatic renal function Prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>tarceva</keyword>
	<keyword>targretin</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>carcinoma , non-small cell lung cancer</keyword>
	<keyword>nsclc</keyword>
</DOC>